CBLPath Revenue and Competitors

Port Chester, NY USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CBLPath's estimated annual revenue is currently $34.3M per year.(i)
  • CBLPath's estimated revenue per employee is $270,000

Employee Data

  • CBLPath has 127 Employees.(i)
  • CBLPath grew their employee count by -2% last year.

CBLPath's People

NameTitleEmail/Phone
1
Co-CEO/CMOReveal Email/Phone
2
VP FinanceReveal Email/Phone
3
VP Quality Assurance, Regulatory and ComplianceReveal Email/Phone
4
Director DermatopathologyReveal Email/Phone
5
Director Breast Pathology at CBLPathReveal Email/Phone
6
Director Accounts ReceivableReveal Email/Phone
7
Lab Operations Manager - Post TechnicalReveal Email/Phone
8
ManagerReveal Email/Phone
9
Manager, Client ServiceReveal Email/Phone
10
Breast PathologistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$54.6M18410%N/AN/A
#2
$321.3M850-9%N/AN/A
#3
$10.2M470%N/AN/A
#4
$24.6M915%N/AN/A
#5
$45.1M15235%N/AN/A
#6
$34M1269%N/AN/A
#7
$28.6M1068%N/AN/A
#8
$6.7M3119%N/AN/A
#9
$73.7M248-3%N/AN/A
#10
$271M7023%$177.7MN/A
Add Company

What Is CBLPath?

CBLPath, Inc. is a leading provider of sub-specialized anatomic pathology and molecular diagnostic laboratory services. We are committed to partnering with our physician-clients to provide the best possible patient care. Founded in 1988 as Cytopath Biopsy Lab, our landmark laboratory quickly established a reputation for providing definitive diagnoses coupled with extraordinary customer service.

keywords:N/A

N/A

Total Funding

127

Number of Employees

$34.3M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CBLPath News

2022-03-22 - After living near Chernobyl, these Pitt researchers set their ...

UPMC licensed ThyroSeq from the University in 2017 and partnered with CBLPath, Inc., a branch of the Austin, Texas-based Sonic Healthcare...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$39.9M1487%N/A
#2
$31.7M1602%N/A
#3
$45.2M23950%N/A
#4
$50.3M2542%N/A
#5
$82.1M294N/AN/A